Peer Exchange

LAI Antipsychotics in Schizophrenia: Clinician's Role
April 16, 2019 – 
Insight regarding the role of the clinician in recommending and educating patients on the efficacy of long-acting injectable antipsychotics for the treatment of schizophrenia.
LAI Antipsychotics in Schizophrenia: Tolerability
April 16, 2019 – 
Experts in the management of patients with schizophrenia comment on the safety profiles of long-acting injectable therapies versus oral agents for the treatment of schizophrenia.
LAI Antipsychotics: Treatment Selection in Schizophrenia
April 08, 2019 – 
Considerations for selecting an appropriate long-acting injectable antipsychotic for the treatment of a patient with schizophrenia.
LAI Antipsychotics: Establishing a Treatment Plan
April 08, 2019 – 
Best practices for counseling patients on the efficacy of long-acting injectables for the treatment of schizophrenia and working with them to understand their treatment plan.
Underutilization of LAI Antipsychotics in Schizophrenia
April 01, 2019 – 
Experts remark on the underutilization of long-acting injectables for the treatment of patients with schizophrenia.
Effects of Schizophrenia Relapse on Hospitalization
April 01, 2019 – 
An expert discussion on schizophrenia relapses and patient hospitalization.
Preventing Relapses in Schizophrenia
March 25, 2019 – 
Insight regarding treatment resistance in schizophrenia and recommendations for ensuring optimal use of antipsychotic therapy to reduce the risk of relapse.
Consequences of Relapses in Schizophrenia
March 25, 2019 – 
Clinicians review the consequences of relapses on patients with schizophrenia and provide insight on counseling patients on the proper use of antipsychotic therapy.
 
Predictors of Relapse in Schizophrenia
March 18, 2019 – 
Experts in the management of patients with schizophrenia highlight typical predictors of relapse and stress the importance of counseling patients on what to monitor for.
Current Challenges in the Treatment of Schizophrenia
March 18, 2019 – 
Challenges surrounding the treatment of patients with schizophrenia and their overall impact on patient care and rates of relapse.
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.